$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 09 Nov 2016 | 31930 | In Stock
Related Topics: Protein

Introduction

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 5

    Introduction 6

    Global Markets Direct Report Coverage 6

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Overview 7

    Therapeutics Development 8

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Stage of Development 8

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Therapy Area 9

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Indication 10

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Products Glance 12

    Late Stage Products 12

    Early Stage Products 13

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Companies 14

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Universities/Institutes 17

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment 19

    Assessment by Monotherapy/Combination Products 19

    Assessment by Mechanism of Action 20

    Assessment by Route of Administration 21

    Assessment by Molecule Type 23

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 25

    Array BioPharma Inc. 25

    Bristol-Myers Squibb Company 26

    Genentech, Inc. 27

    Nimbus Therapeutics, LLC 28

    Pfizer Inc. 29

    Portola Pharmaceuticals, Inc. 30

    Sareum Holdings Plc 31

    Takeda Pharmaceutical Company Limited 32

    Theravance Biopharma Inc 33

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles 34

    ARRY-111 - Drug Profile 34

    Product Description 34

    Mechanism Of Action 34

    R&D Progress 34

    cerdulatinib - Drug Profile 35

    Product Description 35

    Mechanism Of Action 35

    R&D Progress 35

    PF-06700841 - Drug Profile 38

    Product Description 38

    Mechanism Of Action 38

    R&D Progress 38

    SAR-20347 - Drug Profile 39

    Product Description 39

    Mechanism Of Action 39

    R&D Progress 39

    SART-1 - Drug Profile 41

    Product Description 41

    Mechanism Of Action 41

    R&D Progress 41

    SART-29 - Drug Profile 42

    Product Description 42

    Mechanism Of Action 42

    R&D Progress 42

    SART-33 - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    Small Molecule to Inhibit TYK2 for Immunology - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    Small Molecule to Inhibit TYK2 for Psoriasis and IBD - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    Small Molecules to Inhibit TYK2 - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    Small Molecules to Inhibit Tyk2 for Oncology, Psoriasis and IBD - Drug Profile 47

    Product Description 47

    Mechanism Of Action 47

    R&D Progress 47

    Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile 48

    Product Description 48

    Mechanism Of Action 48

    R&D Progress 48

    TD-1473 - Drug Profile 49

    Product Description 49

    Mechanism Of Action 49

    R&D Progress 49

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Projects 51

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products 52

    Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Featured News & Press Releases 53

    Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study 53

    Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis 53

    Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 54

    Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 55

    Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 56

    Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 57

    Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 58

    Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 58

    Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs 59

    Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 60

    Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK 60

    May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib 61

    May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting 63

    Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme 64

    Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting 64

    Appendix 66

    Methodology 66

    Coverage 66

    Secondary Research 66

    Primary Research 66

    Expert Panel Validation 66

    Contact Us 66

    Disclaimer 67

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

31930 | GMDHC0645TDB

Number of Pages

67

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 o...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD8...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018Sum...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2018
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Tra...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2016
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or ...
26 Oct 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2016SummaryGlobal Mar...
26 Oct 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016
Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Pipeline Review, H2 2016...
26 Oct 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembr...
26 Oct 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Receptor BioLogix, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryMarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments r...
15 Apr 2016 by Marketline USD $308 (normally
USD $350)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...